ArticleBMC nephrology2026
Chronic kidney disease (stages 3-5) in children at Chris Hani Baragwanath Academic Hospital, 2000-2019.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe epidemiology and outcome of chronic kidney disease (CKD) in children of less resourced countries are largely underreported.
methodsA retrospective follow-up study of children 2 to 14 years old with CKD stage 3 to 5 at Chris Hani Baragwanath Academic Hospital (CHBAH), South Africa, from 2000 to 2019.
resultsOne hundred and ninety-eight children were analysed. Sixty-five (32.8%), 47 (23.7%), and 86 (43.4%) had CKD stages 3, 4 and 5 at diagnosis, respectively. The median (inter quartile range (IQR) age at diagnosis was 7 (4–11) years and duration of follow up was 1.2 (0.3–3.2) years. The calculated annual incidence in 2001 to 2019 ranged from 9.3 to 29.7 per million age-related population (PMARP). Overall, glomerular disease accounted for 74 (37%); congenital anomalies of the kidney and urinary tract (CAKUT) for 64 (32%). At final outcome, 108 children had CKD stage 5. Seventy-three (67.5%) received kidney replacement therapy (KRT) and 35 (32.4%) treated conservatively. The mean rate of decline in eGFR from baseline to final visit was 4.90 (SD 7.03) ml/min/BSA per year. The mortality rate was 9.8 (95%CI:7.3 to 13.1) per 100 person-years (PY), contributed by 46 (23.3%) children. The two-year survival for glomerular disease was 50% compared to 90% for CAKUT. Risk of mortality increased in CKD stage 5 (AHR = 4.1; 95%CI:1.9–8.9, p-value < 0.001), hypoalbuminemia (AHR = 2.7; 95%CI:1.3–5.6, p-value 0.007) and glomerular disease (AHR = 2.2; 95%CI:1.0-4.8, p-value 0.048).
conclusionThis cohort presented in chronic kidney failure. Barriers to access of kidney services need to be addressed to achieve sustainable developmental goals (SDG).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.